A Phase IIb Clinical Study to Assess the Pharmacokinetics, Safety, and Efficacy of the Combination Regimen of Elbasvir (EBR)/Grazoprevir (GZR) in Participants Aged 3 to less than 18 Years with Chronic Hepatitis C Infection
Phase of Trial: Phase II
Latest Information Update: 02 Jan 2019
At a glance
- Drugs Elbasvir/grazoprevir (Primary) ; Elbasvir; Grazoprevir
- Indications Hepatitis C
- Focus Pharmacokinetics
- Sponsors Merck Sharp & Dohme
- 20 Dec 2018 Planned End Date changed from 17 Jun 2020 to 17 Jul 2020.
- 20 Dec 2018 Planned primary completion date changed from 25 Mar 2020 to 1 Dec 2019.
- 22 Jun 2018 Planned End Date changed from 9 Apr 2020 to 17 Jun 2020.